Clinical trials: Type 1 Diabetes (Juvenile Onset)
Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes
Effect of a Structured Educational Intervention Through Mobile App on Hemoglobin A1c (HbA1c), Self-Efficacy and Self- Care in Adolescent With Type 1 Diabetes (T1DM)
This study aims to evaluate the effectiveness of a mobile health (mHealth) educational intervention for adolescents with Type 1 Diabetes Mellitus (T1DM).
- Conditions
- Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Mellitus, HbA1c
- Trial name
- (T1DM) (NCT07689318)
- Testing
- educational intervention via mobile app
- Volunteers
- 84 people
- Sponsor
- Shifa Tameer-e-Millat University
Atherosclerotic Cardiovascular Disease, Childhood Diabetes Mellitus
Atherosclerotic Cardiovascular Risk in Childhood and Teen-age Onset Diabetes
For children and adolescents with diabetes, the pathological process of atherosclerotic cardiovascular disease(ASCVD) can exist in early childhood and progress rapidly to subclinical ASCVD.
- Conditions
- Atherosclerotic Cardiovascular Disease, Childhood Diabetes Mellitus, Juvenile Diabetes
- Trial name
- NCT05294653
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Diabetes Mellitus, Type 1
GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)
The objectives of the main study is to: Evaluate the safety of giving GAD-Alum (Glutamic acid decarboxylase) (Diamyd) directly into lymph glands in combination with an oral vitamin D regimen Evaluate how the above mentioned…
- Trial name
- DIAGNODE (NCT02352974)
- Testing
- GAD-Alum, Vitamin D
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Johnny Ludvigsson
Type 1 Diabetes Mellitus
Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus
A study to examine the effect of pioglitazone on the course of new onset type 1 diabetes mellitus.
- Trial name
- NCT00545857
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stony Brook University
Diabetes Mellitus, Type 1, Type 1 Diabetes
Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth
This is a study assessing the feasibility of using the insulin-only configuration of the iLet bionic pancreas with initiation in pump-naïve people with type 1 diabetes in a primary care practice with either in-person training and…
- Conditions
- Diabetes Mellitus, Type 1, Type 1 Diabetes, Diabetes, Autoimmune, Diabetes type1
- Trial name
- NCT05168657
- Testing
- Bionic Pancreas, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 1
Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study
The primary goal is to test the function of the Diabetes Assistant (DiAs) enhanced control-to-range (CTR) controller in a closely monitored diabetes camp setting. The camp setting will allow us to obtain pilot efficacy data.
- Trial name
- NCT01973413
- Testing
- Diabetes Assistant (DiAs), Tandem t:slim Insulin Pump, Dexcom G4 Platinum sensor
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Virginia
Diabetes Mellitus, Type 1
Allogenic Islet Cell Transplantation
The purpose of this study is to determine the safety of transplanting human islet cells for controlling hyperglycemia in brittle and/or complex patients with type 1 diabetes.
- Trial name
- NCT00160732
- Testing
- Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
Diabetes Mellitus, Type 1
Family Management of Type 1 Diabetes in Children
This is a multi-center, randomized controlled trial to test whether a clinic-integrated, low intensity, multi-component behavioral intervention is effective in preventing the deterioration in glycemic control, treatment…
- Trial name
- NCT00273286
- Testing
- family diabetes management intervention
- Where
- 4 sites in United States
- Volunteers
- 422 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Type 1 Diabetes (Juvenile Onset), Continuous Glucose Monitoring System
Mediterranean Diet and Oxidative Stress in Type 1 Diabetes (MEDOX-T1D)
Achieving optimal glycemic control in type 1 diabetes requires a holistic approach that includes individualized medical nutrition therapy in addition to appropriate insulin therapy.
- Conditions
- Type 1 Diabetes (Juvenile Onset), Continuous Glucose Monitoring System, Oxidative Stress
- Trial name
- MEDOX-T1D (NCT07544368)
- Testing
- Mediterranean Diet Intervention
- Volunteers
- 54 people
- Sponsor
- Istanbul University
Diabetes Mellitus, Type 1
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes
Anti-CD3 monoclonal antibody (a.k.a. hOKT3gamma1 [Ala-Ala],teplizumab, MGA031) is a humanized antibody that is commonly used to prevent organ rejection.
- Trial name
- AbATE (NCT00129259)
- Testing
- Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes
Effects Of Gamma Aminobutyric Acid On The Progression Of New Onset Juvenile Type 1 Diabetes
This study is a multicenter, randomized, double-masked, placebo-controlled clinical study. All groups will receive standard intensive diabetes treatment with insulin and life style management.
- Trial name
- NCT01781884
- Testing
- Gamma Aminobutyric Acid (GABA)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
Diabetes Mellitus, Type 1
Proleukin and Rapamune in Type 1 Diabetes
This is a phase I trial in individuals who have been diagnosed with type 1 diabetes within the previous 3-48 months. The study is testing whether two immune system modifying drugs are safe when used in combination and if they…
- Trial name
- NCT00525889
- Testing
- IL-2, Rapamycin
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Type 1 diabetes is a condition that is caused in part by an abnormality of the immune system which occurs when T cells, which are part of the immune system, damage the insulin secreting cells (islet cells) in the pancreas.
- Trial name
- NCT00212329
- Testing
- T Cell Proliferation and Autoreactivity Assays, Cellular Immunoblot Assays, Tetramer Studies
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes, Insulin Dependent Diabetes
Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus
The primary objective of this study is to evaluate the action of DPP-IV inhibitors in the prevention of progressive beta cell dysfunction in patients with type 1 diabetes mellitus newly diagnosis ( less than 6 months).
- Conditions
- Type 1 Diabetes, Insulin Dependent Diabetes, Juvenile Onset Diabetes Mellitus, Autoimmune Diabetes
- Trial name
- NCT01559025
- Testing
- Vildagliptin
- Where
- Brazil
- Volunteers
- 44 people
- Sponsor
- Federal University of São Paulo
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Diabetes Mellitus, Type 1
Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials
OBJECTIVE: This study is being conducted by the Type 1 Diabetes TrialNet Study Group, funded by the National Institutes of Health, in collaboration with the European C-Peptide Group.
- Trial name
- NCT00105352
- Testing
- Mixed Meal Tolerance Test, Glucagon Stimulation Test
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
The purpose of this study is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo infusion.
- Trial name
- DEFEND-1 (NCT00678886)
- Testing
- otelixizumab infusion plus physician determined standard of care
- Where
- 109 sites in United States, Canada and 7 more
- Volunteers
- 272 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes Mellitus
Rituximab in New Onset Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks the insulin-producing beta cells in the pancreas.
- Trial name
- TN05 (NCT00279305)
- Testing
- Anti-CD20 (rituximab)
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 87 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes Mellitus, T1D
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103.
- Conditions
- Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
- Trial name
- NCT06783309
- Testing
- CNP-103
- Where
- 45 sites in United States
- Volunteers
- 72 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
Type 1 Diabetes Mellitus, Autoimmune Diabetes
Medtronic Minimed Overnight Closed-Loop System
To test the function and safety of the Medtronic Overnight Closed Loop (OCL) System in a closely monitored 12 hour overnight inpatient study.
- Conditions
- Type 1 Diabetes Mellitus, Autoimmune Diabetes, Juvenile-Onset Diabetes, Diabetes, Mellitus, Type 1
- Trial name
- NCT01881009
- Testing
- Hybrid Closed-loop System, Sensor-augmented pump
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Bruce A. Buckingham